Effects of Resveratrol Supplementation on Nonalcoholic Fatty Liver Disease Management

Abstract

In this study, we aimed to systematically review the studies that investigated the effect of resveratrol in nonalcoholic fatty liver disease (NAFLD). A systematic search of different databases was conducted until June 2021 and a meta-analysis was completed. Six trials involving 232 participants were included. The meta-analysis results showed that serum triglycerides (P = .04), interleukin-6 (P = .01), tumor necrosis factor-α (P = .02), and systolic blood pressure (P = .04) levels were decreased significantly in the resveratrol group compared with the placebo group, while other parameters were not changed significantly. Although resveratrol might attenuate NAFLD development, more high-quality trials are required in this field.